One study shows that olive oil could have preventive properties against triple-negative breast cancer
The results of this work, conducted by researchers at Jaén University Hospital in collaboration with Genyo, have been published in the international journal European Journal of Nutrition
The research group of the Department of Clinical Management of Medical Oncology at the University Hospital in Jaén, directed by Dr. Sergio Granados, succeeded in identifying chemopreventive properties in a component of extra virgin olive oil and table olives called hydroxytyrosol. This finding makes this compound a candidate to be investigated as an alternative targeted therapy for triple negative breast cancer (CMTN), one of the most aggressive.
This study, the results of which were published in the international journal European Journal of Nutrition, was made with different cell lines in vitro of the disease and it has been shown that hydroxytrisol acts directly on cancer stem cells responsible for the relapses of metastatic tumors, reducing their number and ability to generate more cells of this type.
The researchers also showed that this compound lowers both the aggressiveness and the ability to migrate and invade tumor cells of this type of cancer and therefore its metastatic potential
Breast cancer is commonly associated with an increased incidence and mortality rate in women. In particular, CMTN is a very aggressive form of breast cancer characterized by a low survival rate, increased proliferation and a heterogeneity of cancer cells, a high probability of producing metastases and usually leading to drug resistance and the incidence of cancer. relapse. In addition, there are not many therapies for its treatment.
Hydroxitrosol is a phytochemical polyphenol with antioxidant properties and is considered one of the most powerful natural antioxidants. In nature it is present in olives, focusing mainly on leaves, extra virgin olive oil and table olives. This makes it a predominant element of the Mediterranean diet.
The results of this study are the previous stage of testing for hydroxytrisol in xenograft animal models from CMTN patients. Also, this research is the basis of a clinical study that studies the effects of hydroxytrisol in preventing breast cancer in high-risk patients taking place in the hospital The Methodist Hospital in Houston from Houston (United States), where Dr. Granados collaborates.
This research project, run in collaboration with the Pfizer Center – Granada University – Autonomous Government of Genomics And Oncology Research (Genyo), was funded by the Healthcare Strategic Action of the Carlos III Health Institute, Fibao being a management of the project. Currently, the Dr. Granados group is requesting funding that allows it to continue research and incorporate staff to develop a new therapeutic strategy for CMTN patients.
About the research group
The research group led by Dr. Sergio Granados Principal (Miguel Servet Type I researcher) is working at the medical oncology clinic unit of the Jaén University Hospital and in the laboratories of the Pfizer Center – Granada University – Genomics and Research Andalusia Oncology (Genyo). Since 2015, he has devoted his efforts to the search for biomarkers linked to metastatic events, tumor recurrence and resistance to therapy, and where tumor stem cells are the central focus of the study to design new specific therapies and facilitate personalized medicine, particularly patients with CMTN.